ArticleUrolithiasis2026
Calcium oxalate crystals exacerbate the damage and inflammation of renal tubular epithelial cells by blocking autophagic flux.
Article in Urolithiasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Kidney stones, as prevalent crystalline disorders within the urinary system, pose significant clinical challenges due to their high incidence and recurrence rates. The lack of clear pathological mechanisms has limited therapeutic options to surgical interventions without effective preventive strategies. In this study, integrated in vitro and in vivo models revealed that calcium oxalate (CaOx) exposure induced concurrent accumulation of LC3B-II and p62 autophagy markers. Blockade of autophagic flux at the late stage was validated via mCherry-GFP-LC3 dual fluorescence assays, demonstrating impaired autolysosome formation. Mechanistically, autophagic flux obstruction triggered oxidative stress, apoptosis, and proinflammatory cascades, collectively exacerbating renal tubular injury. Pharmacological inhibition of autophagy initiation with 3-methyladenine (3-MA) disrupted the maladaptive autophagy-reinforcement cycle, improving cellular viability and renal function. Conversely, lysosomal acidification blockade via bafilomycin A1 (BafA1) failed to mitigate cytotoxicity. Molecular screening identified specific downregulation of VAMP7-a SNARE complex component critical for autophagosome-lysosome fusion-as the primary mediator of CaOx-induced fusion defects. Overexpression of VAMP7 restored autophagic homeostasis and attenuated crystallotoxicity. This work pioneers a phase-specific autophagy targeting strategy: either suppression of pathological autophagic overactivation or restoration of terminal fusion machinery effectively alleviates CaOx nephrotoxicity. These findings provide a mechanistic foundation for precision therapeutics in stone disease management.
Indexed as
Identifiers
41940969What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.